Tibor Bakács

1.2k total citations
76 papers, 837 citations indexed

About

Tibor Bakács is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Tibor Bakács has authored 76 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Immunology, 26 papers in Oncology and 15 papers in Epidemiology. Recurrent topics in Tibor Bakács's work include Immune Cell Function and Interaction (18 papers), Cancer Immunotherapy and Biomarkers (16 papers) and T-cell and B-cell Immunology (16 papers). Tibor Bakács is often cited by papers focused on Immune Cell Function and Interaction (18 papers), Cancer Immunotherapy and Biomarkers (16 papers) and T-cell and B-cell Immunology (16 papers). Tibor Bakács collaborates with scholars based in Hungary, United Kingdom and United States. Tibor Bakács's co-authors include Ralph W. Moss, J.N. Mehrishi, P Gergely, Eva Klein, Imre Kovesdi, George Klein, László K. Csatáry, David M. Segal, Michael Steinitz and Giuseppe Sconocchia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Tibor Bakács

74 papers receiving 754 citations

Peers

Countries citing papers authored by Tibor Bakács

Since Specialization

Citations

This map shows the geographic impact of Tibor Bakács's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tibor Bakács with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tibor Bakács more than expected).

Fields of papers citing papers by Tibor Bakács

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tibor Bakács. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tibor Bakács. The network helps show where Tibor Bakács may publish in the future.

Co-authorship network of co-authors of Tibor Bakács

This figure shows the co-authorship network connecting the top 25 collaborators of Tibor Bakács. A scholar is included among the top collaborators of Tibor Bakács based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tibor Bakács. Tibor Bakács is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality 2022 ·Cureus ·Tibor Bakács, Rifaat Safadi, László G. Puskás, Liliána Z. Fehér, Imre Kovesdi	5
2	Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies 2020 ·Cancer Immunology Immunotherapy ·Csaba Kerepesi, Tibor Bakács, Ralph W. Moss, Shimon Slavin, Colin C. Anderson	16
3	Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution 2020 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), Andreas Baierl, (unknown), Hans Bojar, Dwight L. McKee, Ralph W. Moss, Nils H. Thoennissen, Attila Marcell Szász, Tibor Bakács	31
4	MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response 2019 ·Theoretical Biology and Medical Modelling ·Csaba Kerepesi, Tibor Bakács, Tamás Szabados	3
5	Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs 2018 ·SHILAP Revista de lepidopterología ·Tibor Bakács, Rifaat Safadi, Imre Kovesdi	5
6	Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency 2014 ·Immunobiology ·Tibor Bakács, J.N. Mehrishi	9
7	Ipilimumab (Yervoy) and the TGN1412 catastrophe 2011 ·Immunobiology ·Tibor Bakács, J.N. Mehrishi, Ralph W. Moss	32
8	Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering? 2010 ·BMC Cancer ·Tibor Bakács, J.N. Mehrishi	7
9	T Cells Survey the Stability of the Self: A Testable Hypothesis on the Homeostatic Role of TCR-MHC Interactions 2007 ·International Archives of Allergy and Immunology ·Tibor Bakács, J.N. Mehrishi, Tamás Szabados, (unknown), (unknown), Gábor Tusnády	8
10	Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus 2004 ·Vaccine ·Tibor Bakács	8
11	Some Aspects of Complementarity in the Immune System 2001 ·International Archives of Allergy and Immunology ·Tibor Bakács, J.N. Mehrishi, Tamás Szabados, László Varga, Gábor Tusnády	3
12	Comparison of the ability of red cells sensitized with a bispecific anti-D × anti-FcγRIII Fab fragment to activate human K cells and peritoneal macrophages through FcγRIII 1994 ·Immunology Letters ·Tibor Bakács, Andrew G. Hadley, Belinda M. Kumpel, David M. Segal, Ferenc Bánhidy	1
13	Interactions in the complement-mediated lysis of blood group AB erythrocytes sensitized simultaneously with anti-A and anti-B monoclonal antibodies 1993 ·Immunology Letters ·Tibor Bakács, (unknown), Anthony H. Merry, Robert B. Sim, (unknown), (unknown), Gábor Tusnády, Eva Klein	4
14	Comparison of lysis of bromelain and papain treated red cells in ADCC assays 1992 ·Immunology Letters ·Belinda M. Kumpel, Tibor Bakács	4
15	Inhibition of the classical activation pathway of complement‐mediated lysis by monoclonal antibodies to complement components C3c and C3d 1992 ·Transfusion ·Rosey Mushens, Tibor Bakács	0
16	Haemolysis mediated by anti-D monoclonal antibodies in direct and cold target competition ADCC assays 1992 ·Immunology Letters ·Tibor Bakács, Belinda M. Kumpel, Gábor Tusnády	2
17	The Role of Antibody Density in the Immune Lysis of Sensitised Erythrocytes: A Mathematical Appreciation 1989 ·Vox Sanguinis ·Tibor Bakács, (unknown), (unknown), Ian Kimber	2
18	Quantitative comparison of direct and cold-target competition assay in monocyte- and complement-mediated lysis of sensitized erythrocytes 1987 ·Immunology Letters ·Tibor Bakács, Klára Tótpál, (unknown), Eva Klein	2
19	[Incidence of HLA-antigens and cytotoxic capacity of lymphocytes in patients with breast cancer]. 1980 ·PubMed ·(unknown), É Gyódi, Tibor Bakács, (unknown), (unknown)	1
20	Polimyelitis prophylaxis in Hungary. 1960 ·PubMed ·Tibor Bakács	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact